IBI-354

Innovent Biologics will showcase seven oral presentations at ASCO 2025, featuring breakthrough clinical data for its novel PD-1/IL-2α-bias bispecific antibody IBI363 in melanoma, colorectal cancer, and non-small cell lung cancer.

Innovent Biologics has dosed the first participant in HeriCare-Ovarian01, the first Phase 3 trial in China investigating IBI354, a novel HER2 ADC, for platinum-resistant ovarian cancer with HER2 expression.

iOnctura has dosed the first patient in its randomized Phase II OCULE-01 study evaluating roginolisib, an allosteric PI3Kδ modulator, in patients with metastatic uveal melanoma.

Innovent's IBI343, an anti-CLDN18.2 ADC, has been granted Breakthrough Therapy Designation (BTD) by China's NMPA for advanced pancreatic cancer.

Mural Oncology's ARTISTRY-7 trial evaluating nemvaleukin with pembrolizumab in platinum-resistant ovarian cancer has reached 75% of overall survival events.